We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Journey Medical Corporation | NASDAQ:DERM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.06 | -1.63% | 3.63 | 3.66 | 3.69 | 3.74 | 3.6002 | 3.68 | 28,536 | 20:07:38 |
NEW YORK, Jan. 10, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Dermira, Inc. (NASDAQ: DERM) and its board of directors concerning the proposed acquisition of the company by Eli Lilly and Company (NYSE: LLY). Stockholders will receive $18.75 per share of Dermira, Inc. common stock that they hold. The transaction is valued at approximately $1.1 billion and is expected to close in the first quarter of 2020.
If you are a stockholder of Dermira, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/derm. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at info@rowleylawpllc.com, or by telephone at 914-400-1920 or 844-400-4643 (toll-free).
Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com.
Attorney Advertising. Prior results do not guarantee a similar outcome.
View original content:http://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-dermira-inc-300985030.html
SOURCE Rowley Law PLLC
Copyright 2020 PR Newswire
1 Year Journey Medical Chart |
1 Month Journey Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions